Sex Hormone Supplementation and Rotator Cuff Repair: A Preliminary Randomized Trial
NCT04944836 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58
Last updated 2026-03-19
Summary
Shoulder tendon tears are a common cause of shoulder pain and disability and after surgery the repaired tendon often does not heal. In this pilot study, men with low sex hormone levels will be randomly assigned to receive sex hormone therapy or placebo pills while healing from tendon repair surgery in their shoulder. Sex hormone therapy increases sex hormone levels, and the investigators will test whether these increased sex hormone levels show promise in improving tendon healing and patient shoulder function and pain.
Conditions
- Rotator Cuff Tears
Interventions
- DRUG
-
Clomiphene Citrate
All patients will receive non-labeled pills identical in appearance from our pharmacy, to be taking once every other day. In the study group, these will contain 50 mg of clomiphene citrate. In the control group, these will be placebo. These will be taken every other day for seven months beginning four weeks prior to surgery and extending for six months after surgery. After enrollment patients will be randomized. Patient will be assigned to the 2 groups using a permuted block randomization scheme with blocks of size 2, 4, and 6. Prior to initiation of the study opaque sealed envelopes will be prepared and thoroughly shuffled and then used sequentially during the study. These randomization assignments will be available to the pharmacy in a web-based format or by cards in sealed envelopes. A nonparticipant in the study (the pharmacy at our institution) will administer this process.
- PROCEDURE
-
Rotator Cuff Repair
The operative protocol will be standardized in all patients. Both the operative protocol and post-operative rehabilitation protocol will be per our standard of care, without alteration. An arthroscopic approach will be used. In all cases a double-row rotator cuff repair using triple-loaded anchor(s) on the medial row will be used. Post-operatively all patients will be placed in a sling for six weeks. Active range of motion exercises will begin at six weeks post-operatively and strengthening will be delayed until 12 weeks post-operatively. In all phases of care our peri-operative and post-operative protocol for study patients will be similar to our current clinical practice to ensure generalizability.
Sponsors & Collaborators
- lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 40 Years
- Max Age
- 80 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-03-09
- Primary Completion
- 2028-07-01
- Completion
- 2029-01-01
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Peri-Operative Testosterone Administration in Primary Total Hip Arthroplasty
NCT06608914 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4
-
Impact of Peri-operative tEstosterone Levels on oNcological and Functional Outcomes in RadiCal prostatEctomy
NCT04833426 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males
NCT02994602 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of Estradiol Addback
NCT01862835 ·Status: COMPLETED ·Phase: PHASE1
-
Testosterone Administration and ACL Reconstruction in Men
NCT01595581 ·Status: COMPLETED ·Phase: PHASE3
-
Exercise and Testosterone Therapy in Elderly Men With Physical Frailty
NCT00345969 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Andriol Testocaps in Symptomatic Late-Onset Hypogonadism (43203)
NCT00434824 ·Status: COMPLETED ·Phase: PHASE2
-
Use of Testosterone to Prevent Post-Surgical Muscle Loss - Pilot Study
NCT04456530 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Testosterone Effects on Bone and Frailty
NCT00182871 ·Status: COMPLETED ·Phase: PHASE4
-
Analgesic Efficacy of Testosterone Replacement in Hypogonadal Opioid-treated Chronic Pain Patients: A Pilot Study.
NCT00398034 ·Status: WITHDRAWN ·Phase: PHASE2
-
Neoadjuvant Estradiol or Androgen Deprivation in Clinically Localized Prostate Cancer
NCT00167648 ·Status: COMPLETED ·Phase: PHASE2
-
Clomiphene Citrate for the Treatment of Low Testosterone Associated With Chronic Opioid Pain Medication Administration
NCT01880086 ·Status: COMPLETED ·Phase: PHASE2
-
Testosterone and Growth Hormone for Bone Loss in Men
NCT00080483 ·Status: COMPLETED ·Phase: PHASE2
-
Effectiveness of Testosterone Undecanoate to Improve Sexual Function in Postmenopausal Women
NCT01724658 ·Status: COMPLETED ·Phase: PHASE2
-
Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism
NCT03887936 ·Status: COMPLETED ·Phase: PHASE4
-
Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men
NCT01104246 ·Status: COMPLETED ·Phase: PHASE1
-
Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans
NCT05442463 ·Status: RECRUITING
-
Testosterone Therapy in Hypogonadal Men Treated With Opioids
NCT02433730 ·Status: COMPLETED ·Phase: PHASE4
-
A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males
NCT02149264 ·Status: COMPLETED ·Phase: PHASE3
-
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
NCT04798469 ·Status: RECRUITING ·Phase: PHASE2
-
Testosterone Treatment in a Patient With 17β-hydroxysteroid Dehydrogenase Type 3 Deficiency: an N-of-1 Study
NCT04831099 ·Status: UNKNOWN ·Phase: PHASE3
-
A Clinical Study to Evaluate the Pharmacokinetics of Testosterone Gel Using an Applicator
NCT01464879 ·Status: COMPLETED ·Phase: PHASE2
-
Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
NCT04049331 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Testosterone Replacement for Fatigue in Male Hypogonadic Advanced Cancer Patients
NCT00965341 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetic and Comparative Bioavailability Study of Testosterone Absorption After Administration of Testosterone Gel 1.62% to the Upper Arms/Shoulders Using an Application Site Rotation or a Combination of Application Sites in Hypogonadal Males
NCT01133548 ·Status: COMPLETED ·Phase: PHASE1